Trends in adverse events of benign prostatic hyperplasia (BPH) in the USA, 1998 to 2008

BJU International

Volumn 109, Issue 1, 2012, Pages 84-87

  Stroup, Sean P ^a,b   Palazzi Churas, Kerrin ^a   Kopp, Ryan P ^a   Parsons, J Kellogg ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

benign prostatic hyperplasia (BPH); epidemiology; Nationwide Inpatient Sample (NIS); outcomes

Indexed keywords

ADULT; ADVERSE OUTCOME; AGE DISTRIBUTION; ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; HOSPITALIZATION; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; UNITED STATES; URINE RETENTION;

AGE FACTORS; AGED; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; FOLLOW-UP STUDIES; HOSPITALIZATION; HUMANS; INPATIENTS; MALE; MIDDLE AGED; PREVALENCE; PROGNOSIS; PROSTATIC HYPERPLASIA; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; UNITED STATES; URINARY RETENTION;

EID: 83555174522     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2011.10250.x     Document Type: Article

References (12)

1. Wei JT, Calhoun E, Jacobsen SJ,. Urologic diseases in America project: benign prostatic hyperplasia. J Urol 2005; 173: 1256-61 (Pubitemid 40380548)
2. Boyle P, Robertson C, Mazzetta C, et al,. The prevalence of lower urinary tract symptoms in men and women in four centres. The UrEpik study. BJU Int 2003; 92: 409-14 (Pubitemid 37100519)
3. Kupelian V, Wei JT, O'Leary MP, et al. Prevalence of lower urinary tract symptoms and effect on quality of life in a racially and ethnically diverse random sample: the Boston Area Community Health (BACH) Survey. Arch Intern Med 2006; 166: 2381-7 (Pubitemid 44833365)
4. Taylor BC, Wilt TJ, Fink HA, et al,. Prevalence, severity, and health correlates of lower urinary tract symptoms among older men: the MrOS study. Urology 2006; 68: 804-9 (Pubitemid 44633362)
5. Trueman P, Hood SC, Nayak US, Mrazek MF,. Prevalence of lower urinary tract symptoms and self-reported diagnosed 'benign prostatic hyperplasia', and their effect on quality of life in a community-based survey of men in the UK. BJU Int 1999; 83: 410-5 (Pubitemid 29151164)
6. Parsons JK, Bergstrom J, Silberstein J, Barrett-Connor E,. Prevalence and characteristics of lower urinary tract symptoms in men aged > or = 80 years. Urology 2008; 72: 318-21
7. Parsons JK,. Commentary on BPH and public health-have we lost the forest through the trees? J Urol 2008; 179 (Suppl.): S81 (Pubitemid 351483906)
8. McConnell JD, Roehrborn CG, Bautista OM, et al,. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; 349: 2387-98 (Pubitemid 37542987)
9. Parsons JK,. Modifiable risk factors for benign prostatic hyperplasia and lower urinary tract symptoms: new approaches to old problems. J Urol 2007; 178: 395-401 (Pubitemid 47030484)
10. Parsons JK, Carter HB, Partin AW, et al,. Metabolic factors associated with benign prostatic hyperplasia. J Clin Endocrinol Metab 2006; 91: 2562-8 (Pubitemid 44024618)
11. Sarma AV, Parsons JK, McVary K, Wei JT,. Diabetes and benign prostatic hyperplasia/lower urinary tract symptoms-what do we know? J Urol 2009; 182 (Suppl.): S32-7
12. Thompson IM, Goodman PJ, Tangen CM, et al,. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003; 349: 215-24 (Pubitemid 36859473)